A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent/refractory central nervous system tumors

被引：0
|
作者：
Jonathan Metts
Brittany Harrington
Emad Salman
Scott M. Bradfield
Jennifer Flanary
Maua Mosha
Ernest Amankwah
Stacie Stapleton
机构：
[1] Johns Hopkins All Children’s Hospital,Cancer and Blood Disorders Institute
[2] Hospital Medicine,Division of Pediatric Hematology/Oncology
[3] MyMichigan Health,Data Coordinating Center for Pediatric Multicenter Studies
[4] Golisano Children’s Hospital of Southwest Florida,Department of Oncology
[5] Nemours Children’s Health,undefined
[6] Institute for Clinical and Translational Research,undefined
[7] Johns Hopkins All Children’s Hospital,undefined
[8] Johns Hopkins University School of Medicine,undefined
来源：
Child's Nervous System | 2022年 / 38卷
关键词：
Phase I; Pediatric; Brain tumor; Irinotecan; Temozolomide; Bevacizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：919 / 928
页数：9
相关论文
共 50 条
  • [1] A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent/refractory central nervous system tumors
    Metts, Jonathan
    Harrington, Brittany
    Salman, Emad
    Bradfield, Scott M.
    Flanary, Jennifer
    Mosha, Maua
    Amankwah, Ernest
    Stapleton, Stacie
    CHILDS NERVOUS SYSTEM, 2022, 38 (05) : 919 - 928
  • [2] Irinotecan and Bevacizumab in Children with Malignant Gliomas and Recurrent/Refractory Central Nervous System Tumors
    Cisneros, Gabriel Salinas
    Dager, Sarah
    Khatib, Ziad
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S52 - S53
  • [3] PHASE I STUDY OF COMBINATION THERAPY WITH BEVAZICUMAB, IRINOTECAN, AND TEMOZOLOMIDE IN CHILDREN WITH HIGH GRADE AND RECURRENT CENTRAL NERVOUS SYSTEM TUMORS
    Stapleton, Stacie
    Flanary, Jennifer
    Hamblin, Frances
    Steinbrueck, Sonja
    Rodriguez, Luis
    Tuite, Gerald
    Carey, Carolyn
    Storrs, Bruce
    Lavey, Robert
    NEURO-ONCOLOGY, 2012, 14 : 16 - 16
  • [4] FEASIBILITY OF COMBINATION THERAPY WITH BEVACIZUMAB, IRINOTECAN, AND TEMOZOLOMIDE IN CHILDREN WITH CENTRAL NERVOUS SYSTEM TUMORS
    Stapleton, S.
    Hamblin, F.
    Steinbrueck, S.
    Bradfield, S.
    Tuite, G.
    Carey, C.
    Storrs, B.
    NEURO-ONCOLOGY, 2010, 12 (06) : II90 - II90
  • [5] Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors
    Robison, Nathan J.
    Yeo, Kee Kiat
    Berliner, Adrian P.
    Malvar, Jemily
    Sheard, Michael A.
    Margol, Ashley S.
    Seeger, Robert C.
    Rushing, Teresa
    Finlay, Jonathan L.
    Sposto, Richard
    Dhall, Girish
    JOURNAL OF NEURO-ONCOLOGY, 2018, 138 (01) : 199 - 207
  • [6] Phase I trial of dasatinib, lenalidomide, and temozolomide in children with relapsed or refractory central nervous system tumors
    Nathan J. Robison
    Kee Kiat Yeo
    Adrian P. Berliner
    Jemily Malvar
    Michael A. Sheard
    Ashley S. Margol
    Robert C. Seeger
    Teresa Rushing
    Jonathan L. Finlay
    Richard Sposto
    Girish Dhall
    Journal of Neuro-Oncology, 2018, 138 : 199 - 207
  • [7] OUTCOMES IN PEDIATRIC MALIGNANT CENTRAL NERVOUS SYSTEM TUMORS UTILIZING TEMOZOLOMIDE, BEVACIZUMAB, AND IRINOTECAN
    Reel, Sarah
    Smiley, Natasha Pillay
    Hummel, Trent
    Lane, Adam
    NEURO-ONCOLOGY, 2023, 25
  • [8] Phase I Study of Bevacizumab Plus Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors
    Okada, Keiko
    Yamasaki, Kai
    Tanaka, Chika
    Fujisaki, Hiroyuki
    Osugi, Yuko
    Hara, Junichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (11) : 1073 - 1079
  • [9] PHASE I TRIAL OF DASATINIB, LENALIDOMIDE, AND TEMOZOLOMIDE IN CHILDREN WITH RELAPSED OR REFRACTORY CENTRAL NERVOUS SYSTEM (CNS) TUMORS
    Dhall, Girish
    Haley, Kelley
    Finlay, Jonathan
    Rushing, Teresa
    Sposto, Richard
    Seeger, Robert
    NEURO-ONCOLOGY, 2013, 15 : 166 - 166
  • [10] Efficacy of Bevacizumab Alone or in Combination with Temozolomide and Irinotecan in the Treatment of Recurrent and Refractory Brain Tumors in Children in Lebanon
    Noun, P.
    Fadlallah, M.
    Hmaimess, G.
    Younis, J. Abi
    Hage, P.
    Al Hamod, D.
    Mansour, H.
    Bechara, E.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S554 - S555
12345